MX2018016074A - Vector adenoviral. - Google Patents
Vector adenoviral.Info
- Publication number
- MX2018016074A MX2018016074A MX2018016074A MX2018016074A MX2018016074A MX 2018016074 A MX2018016074 A MX 2018016074A MX 2018016074 A MX2018016074 A MX 2018016074A MX 2018016074 A MX2018016074 A MX 2018016074A MX 2018016074 A MX2018016074 A MX 2018016074A
- Authority
- MX
- Mexico
- Prior art keywords
- adenovirus
- adenoviral vector
- ady25
- genome
- present
- Prior art date
Links
- 239000013598 vector Substances 0.000 title abstract 4
- 241000701161 unidentified adenovirus Species 0.000 abstract 3
- 108091026890 Coding region Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/235—Adenoviridae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
- C12N15/8613—Chimaeric vector systems comprising heterologous sequences for production of another viral vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10044—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/20—Pseudochromosomes, minichrosomosomes
- C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
La presente invención proporciona vectores adenovirales recombinantes, composiciones inmunogénicas de los mismos y sus usos en medicina. En particular, la presente invención proporciona un vector adenoviral que comprende el genoma de un adenovirus diferente de AdHu5 y AdY25, en donde el genoma del ádenovirus se ha modificado tal que el vector carece del locus E4 nativo del adenovirus y comprende regiones de codificación E4Orf1, E4Orf2 y E4Orf3 heterólogas de AdY25.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1610967.0A GB2549809C (en) | 2016-06-23 | 2016-06-23 | Vector |
PCT/GB2017/051851 WO2017221031A1 (en) | 2016-06-23 | 2017-06-23 | Adenoviral vector |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018016074A true MX2018016074A (es) | 2019-09-09 |
Family
ID=56891578
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018016074A MX2018016074A (es) | 2016-06-23 | 2017-06-23 | Vector adenoviral. |
Country Status (13)
Country | Link |
---|---|
US (2) | US11306325B2 (es) |
EP (2) | EP3475433B9 (es) |
JP (2) | JP7187451B2 (es) |
KR (1) | KR102205908B1 (es) |
CN (1) | CN109790548B (es) |
AU (1) | AU2017282102B2 (es) |
CA (1) | CA3027686A1 (es) |
DK (1) | DK3475433T3 (es) |
ES (1) | ES2883354T3 (es) |
GB (1) | GB2549809C (es) |
MX (1) | MX2018016074A (es) |
SG (1) | SG11201811178UA (es) |
WO (1) | WO2017221031A1 (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102089121B1 (ko) | 2013-03-14 | 2020-03-13 | 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 종양살상형 아데노바이러스 조성물 |
CA3013637A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
CN108699566B (zh) | 2016-02-23 | 2023-06-30 | 萨克生物研究学院 | 对病毒动力学影响最小的治疗性腺病毒中的外源基因表达 |
GB2549809C (en) | 2016-06-23 | 2022-11-30 | Univ Oxford Innovation Ltd | Vector |
CA3045892A1 (en) | 2016-12-12 | 2018-06-21 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
BR112020019942A2 (pt) * | 2018-04-09 | 2021-01-26 | Salk Institute For Biological Studies | composições de adenovírus oncolítico com propriedades de replicação aprimoradas |
GB201812647D0 (en) * | 2018-08-03 | 2018-09-19 | Chancellor Masters And Scholars Of The Univ Of Oxford | Viral vectors and methods for the prevention or treatment of cancer |
GB201814141D0 (en) * | 2018-08-30 | 2018-10-17 | Univ Oxford Innovation Ltd | Method and compositions for producing a virus |
GB201818084D0 (en) * | 2018-11-06 | 2018-12-19 | Univ Oxford Innovation Ltd | Compositions and methods |
CN109602901B (zh) * | 2019-01-08 | 2022-05-27 | 成都迈科康生物科技有限公司 | 一种带状疱疹病毒疫苗及其制备方法和应用 |
TW202110870A (zh) * | 2019-05-30 | 2021-03-16 | 美商葛利史東腫瘤科技公司 | 經修飾之腺病毒 |
CR20220129A (es) | 2019-09-30 | 2022-05-06 | Gilead Sciences Inc | Vacunas para vhb y métodos de tratamiento de vhb |
CN113088530A (zh) * | 2020-01-08 | 2021-07-09 | 怡道生物科技(苏州)有限公司 | 一种基于黑猩猩ChAd63型腺病毒的表达载体及其构建方法 |
CN113088538A (zh) * | 2020-01-08 | 2021-07-09 | 怡道生物科技(苏州)有限公司 | 一种基于黑猩猩ChAd3型腺病毒的表达载体及其构建方法 |
US20230065376A1 (en) * | 2020-02-05 | 2023-03-02 | New York Blood Center, Inc. | Zika virus immunogenic compositions |
RU2720614C9 (ru) * | 2020-04-23 | 2021-02-09 | федеральное государственное бюджетное учреждение «Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи» Министерства здравоохранения Российской Федерации | Иммунобиологическое средство и способ его использования для индукции специфического иммунитета против вируса тяжелого острого респираторного синдрома SARS-CoV-2 (варианты) |
KR20230088301A (ko) * | 2020-08-22 | 2023-06-19 | 페더럴 스테이트 버지터리 인스티튜션 “내셔널 리서치 센터 포 에피데미올로지 앤드 마이크로바이올로지 네임드 애프터 더 아너러리 아카데미시안 엔.에프. 감마레야” 오브 더 미니스트리 오브 헬스 오브 더 러시안 페더레이션 | 중증 급성 호흡기 증후군 바이러스 SARS-CoV-2에 대한 발현 벡터 |
CN112552380B (zh) * | 2020-12-10 | 2021-12-24 | 武汉博沃生物科技有限公司 | 一种SARS-CoV-2病毒的免疫原及其应用 |
WO2022122036A1 (zh) * | 2020-12-10 | 2022-06-16 | 武汉博沃生物科技有限公司 | 一种SARS-CoV-2病毒的免疫原、药物组合物及其应用 |
CN112831524B (zh) * | 2021-02-20 | 2023-06-13 | 苏州相奕生物技术有限公司 | 人工改造的重组腺病毒载体、由其包装的病毒及其应用 |
CN116103242A (zh) * | 2023-01-10 | 2023-05-12 | 潍坊医学院 | 一种靶向治疗结核病的esat6-car-t及其制备方法和应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2553541C (en) * | 2004-01-23 | 2015-04-21 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Chimpanzee adenovirus vaccine carriers |
JP5882741B2 (ja) * | 2009-02-02 | 2016-03-09 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | サルアデノウイルスの核酸配列及びアミノ酸配列、それを含有するベクター、並びにその使用 |
GB201108879D0 (en) * | 2011-05-25 | 2011-07-06 | Isis Innovation | Vector |
BR112014008284A2 (pt) * | 2011-10-05 | 2020-10-27 | Genvec Inc. | adenovirus (gorilla) simian ou vetores adenovirais e métodos de uso |
GB201318084D0 (en) * | 2013-10-11 | 2013-11-27 | Isis Innovation | Malaria vaccination |
PL3062815T3 (pl) * | 2013-11-01 | 2019-07-31 | Pfizer Inc. | Wektory do ekspresji antygenów związanych z gruczołem krokowym |
GB201413530D0 (en) * | 2014-07-30 | 2014-09-10 | Isis Innovation | Treatment and prevention of malaria |
GB2549809C (en) | 2016-06-23 | 2022-11-30 | Univ Oxford Innovation Ltd | Vector |
-
2016
- 2016-06-23 GB GB1610967.0A patent/GB2549809C/en active Active
-
2017
- 2017-06-23 JP JP2019520507A patent/JP7187451B2/ja active Active
- 2017-06-23 EP EP17734440.5A patent/EP3475433B9/en active Active
- 2017-06-23 AU AU2017282102A patent/AU2017282102B2/en active Active
- 2017-06-23 SG SG11201811178UA patent/SG11201811178UA/en unknown
- 2017-06-23 CN CN201780039028.8A patent/CN109790548B/zh active Active
- 2017-06-23 CA CA3027686A patent/CA3027686A1/en active Pending
- 2017-06-23 US US16/310,281 patent/US11306325B2/en active Active
- 2017-06-23 DK DK17734440.5T patent/DK3475433T3/da active
- 2017-06-23 EP EP21182840.5A patent/EP3943604A1/en active Pending
- 2017-06-23 ES ES17734440T patent/ES2883354T3/es active Active
- 2017-06-23 WO PCT/GB2017/051851 patent/WO2017221031A1/en unknown
- 2017-06-23 MX MX2018016074A patent/MX2018016074A/es unknown
- 2017-06-23 KR KR1020197002318A patent/KR102205908B1/ko active IP Right Grant
-
2022
- 2022-01-28 US US17/587,376 patent/US11970709B2/en active Active
- 2022-08-15 JP JP2022129264A patent/JP7333857B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP2019519252A (ja) | 2019-07-11 |
US20220220507A1 (en) | 2022-07-14 |
AU2017282102B2 (en) | 2023-03-23 |
EP3475433A1 (en) | 2019-05-01 |
EP3475433B9 (en) | 2022-08-24 |
CN109790548A (zh) | 2019-05-21 |
EP3943604A1 (en) | 2022-01-26 |
US20190175716A1 (en) | 2019-06-13 |
US11306325B2 (en) | 2022-04-19 |
CN109790548B (zh) | 2024-03-22 |
GB2549809C (en) | 2022-11-30 |
JP2022159418A (ja) | 2022-10-17 |
SG11201811178UA (en) | 2019-01-30 |
JP7187451B2 (ja) | 2022-12-12 |
EP3475433B1 (en) | 2021-07-21 |
GB2549809B (en) | 2019-04-03 |
WO2017221031A1 (en) | 2017-12-28 |
ES2883354T3 (es) | 2021-12-07 |
KR20190020131A (ko) | 2019-02-27 |
CA3027686A1 (en) | 2017-12-28 |
DK3475433T3 (da) | 2021-08-16 |
AU2017282102A1 (en) | 2019-01-03 |
JP7333857B2 (ja) | 2023-08-25 |
GB2549809A (en) | 2017-11-01 |
GB201610967D0 (en) | 2016-08-10 |
US11970709B2 (en) | 2024-04-30 |
KR102205908B1 (ko) | 2021-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018016074A (es) | Vector adenoviral. | |
MX2022003116A (es) | Factor ix modificado, y composiciones, metodos y usos para la transferencia de genes a celulas, organos y tejidos. | |
MX2019006725A (es) | Polinucleotidos y polipeptidos de adenovirus. | |
MX2018001213A (es) | Nuevos metodos para inducir una respuesta inmunitaria. | |
GB2557123A (en) | Modified cells and methods of therapy | |
MX2016014187A (es) | Adenovirus que comprende una fraccion de union a albumina. | |
GT201700214A (es) | Producción de vectores adeno-asociados de gran tamaño | |
MX2020003596A (es) | Composiciones de acido nucleico-polipeptido y usos de las mismos. | |
MX2017008449A (es) | Polipeptido de pirina y modulacion inmune. | |
MX2023004479A (es) | Sistema de vector multiple y sus usos. | |
MY190926A (en) | Cpg reduced factor viii variants, compositions and methods and uses for treatment of hemostasis disorders | |
MX2021001460A (es) | Metodos y composiciones para secrecion de polipeptidos heterologos. | |
MX2020011568A (es) | Polimeros de proteina de leche recombinante. | |
PH12019500591A1 (en) | Canine adenovirus vectors | |
MX2019007152A (es) | Peptido novedoso. | |
MX2019008105A (es) | Virus. | |
MX2020001885A (es) | Formulaciones de daptomicina. | |
WO2016058512A8 (zh) | 马拉巴石斑鱼Piscidin的改造体抗菌肽及其应用 | |
AU2015279552A8 (en) | Neural cells expressing adenovirus E4ORF1, and methods of making and using the same | |
MX2018001055A (es) | Promotores para mejorar la expresion en poxvirus. | |
MX2017010883A (es) | Composicion para el tratamiento de la infertilidad. | |
MX2020013553A (es) | Polinucleotidos y polipeptidos de adenovirus. | |
GB201821082D0 (en) | Combination of complement factors i and h, and vector encoding thereof | |
MX2021002041A (es) | Terapia génica para el tratamiento de galactosemia. | |
PH12018501183A1 (en) | Method of preparing porcine circovirus type 2 capsid protein and pharmaceutical composition comprising same |